CDK4 inhibition restores G₁-S arrest in MYCN-amplified neuroblastoma cells in the context of doxorubicin-induced DNA damage

References

• D’Angio GJ, Evans AE, Koop CE. Special pattern of widespread neuroblastoma with a favourable prognosis. Lancet 1971; 1:1046 - 9; http://dx.doi.org/10.1016/S0140-6736(71)91606-0; PMID: 4102970
   PubMed Web of Science ®Google Scholar
• Haas D, Ablin AR, Miller C, Zoger S, Matthay KK. Complete pathologic maturation and regression of stage IVS neuroblastoma without treatment. Cancer 1988; 62:818 - 25; http://dx.doi.org/10.1002/1097-0142(19880815)62:4<818::AID-CNCR2820620430>3.0.CO;2-K; PMID: 3293764
   PubMed Web of Science ®Google Scholar
• Evans AE, Gerson J, Schnaufer L. Spontaneous regression of neuroblastoma. Natl Cancer Inst Monogr 1976; 44:49 - 54; PMID: 1030781
   PubMedGoogle Scholar
• De Bernardi B, Nicolas B, Boni L, Indolfi P, Carli M, Cordero Di Montezemolo L, et al, Italian Co-Operative Group for Neuroblastoma. Disseminated neuroblastoma in children older than one year at diagnosis: comparable results with three consecutive high-dose protocols adopted by the Italian Co-Operative Group for Neuroblastoma. J Clin Oncol 2003; 21:1592 - 601; http://dx.doi.org/10.1200/JCO.2003.05.191; PMID: 12697885
   PubMed Web of Science ®Google Scholar
• Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, et al, Children’s Cancer Group. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. N Engl J Med 1999; 341:1165 - 73; http://dx.doi.org/10.1056/NEJM199910143411601; PMID: 10519894
   PubMed Web of Science ®Google Scholar
• Zage PE, Kletzel M, Murray K, Marcus R, Castleberry R, Zhang Y, et al, Children’s Oncology Group. Outcomes of the POG 9340/9341/9342 trials for children with high-risk neuroblastoma: a report from the Children’s Oncology Group. Pediatr Blood Cancer 2008; 51:747 - 53; http://dx.doi.org/10.1002/pbc.21713; PMID: 18704922
   PubMed Web of Science ®Google Scholar
• Seeger RC, Brodeur GM, Sather H, Dalton A, Siegel SE, Wong KY, et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 1985; 313:1111 - 6; http://dx.doi.org/10.1056/NEJM198510313131802; PMID: 4047115
   PubMed Web of Science ®Google Scholar
• Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 1984; 224:1121 - 4; http://dx.doi.org/10.1126/science.6719137; PMID: 6719137
   PubMed Web of Science ®Google Scholar
• Fulda S, Lutz W, Schwab M, Debatin KM. MycN sensitizes neuroblastoma cells for drug-induced apoptosis. Oncogene 1999; 18:1479 - 86; http://dx.doi.org/10.1038/sj.onc.1202435; PMID: 10050884
   PubMed Web of Science ®Google Scholar
• Lutz W, Fulda S, Jeremias I, Debatin KM, Schwab M. MycN and IFNgamma cooperate in apoptosis of human neuroblastoma cells. Oncogene 1998; 17:339 - 46; http://dx.doi.org/10.1038/sj.onc.1200201; PMID: 9690515
   PubMed Web of Science ®Google Scholar
• Paffhausen T, Schwab M, Westermann F. Targeted MYCN expression affects cytotoxic potential of chemotherapeutic drugs in neuroblastoma cells. Cancer Lett 2007; 250:17 - 24; http://dx.doi.org/10.1016/j.canlet.2006.09.010; PMID: 17141950
   PubMed Web of Science ®Google Scholar
• Bell E, Premkumar R, Carr J, Lu X, Lovat PE, Kees UR, et al. The role of MYCN in the failure of MYCN amplified neuroblastoma cell lines to G1 arrest after DNA damage. Cell Cycle 2006; 5:2639 - 47; http://dx.doi.org/10.4161/cc.5.22.3443; PMID: 17172827
   PubMed Web of Science ®Google Scholar
• Chen L, Iraci N, Gherardi S, Gamble LD, Wood KM, Perini G, et al. p53 is a direct transcriptional target of MYCN in neuroblastoma. Cancer Res 2010; 70:1377 - 88; http://dx.doi.org/10.1158/0008-5472.CAN-09-2598; PMID: 20145147
   PubMed Web of Science ®Google Scholar
• Knudsen KE, Booth D, Naderi S, Sever-Chroneos Z, Fribourg AF, Hunton IC, et al. RB-dependent S-phase response to DNA damage. Mol Cell Biol 2000; 20:7751 - 63; http://dx.doi.org/10.1128/MCB.20.20.7751-7763.2000; PMID: 11003670
   PubMed Web of Science ®Google Scholar
• Mayhew CN, Perkin LM, Zhang X, Sage J, Jacks T, Knudsen ES. Discrete signaling pathways participate in RB-dependent responses to chemotherapeutic agents. Oncogene 2004; 23:4107 - 20; http://dx.doi.org/10.1038/sj.onc.1207503; PMID: 15064736
   PubMed Web of Science ®Google Scholar
• Harrington EA, Bruce JL, Harlow E, Dyson N. pRB plays an essential role in cell cycle arrest induced by DNA damage. Proc Natl Acad Sci USA 1998; 95:11945 - 50; http://dx.doi.org/10.1073/pnas.95.20.11945; PMID: 9751770
   PubMed Web of Science ®Google Scholar
• Brugarolas J, Moberg K, Boyd SD, Taya Y, Jacks T, Lees JA. Inhibition of cyclin-dependent kinase 2 by p21 is necessary for retinoblastoma protein-mediated G1 arrest after gamma-irradiation. Proc Natl Acad Sci USA 1999; 96:1002 - 7; http://dx.doi.org/10.1073/pnas.96.3.1002; PMID: 9927683
   PubMed Web of Science ®Google Scholar
• Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, et al. p53 status and the efficacy of cancer therapy in vivo. Science 1994; 266:807 - 10; http://dx.doi.org/10.1126/science.7973635; PMID: 7973635
   PubMed Web of Science ®Google Scholar
• Carr-Wilkinson J, O’Toole K, Wood KM, Challen CC, Baker AG, Board JR, et al. High Frequency of p53/MDM2/p14ARF Pathway Abnormalities in Relapsed Neuroblastoma. Clin Cancer Res 2010; 16:1108 - 18; http://dx.doi.org/10.1158/1078-0432.CCR-09-1865; PMID: 20145180
   PubMed Web of Science ®Google Scholar
• Bell E, Chen L, Liu T, Marshall GM, Lunec J, Tweddle DA. MYCN oncoprotein targets and their therapeutic potential. Cancer Lett 2010; 293:144 - 57; http://dx.doi.org/10.1016/j.canlet.2010.01.015; PMID: 20153925
   PubMed Web of Science ®Google Scholar
• Tweddle DA, Pearson AD, Haber M, Norris MD, Xue C, Flemming C, et al. The p53 pathway and its inactivation in neuroblastoma. Cancer Lett 2003; 197:93 - 8; http://dx.doi.org/10.1016/S0304-3835(03)00088-0; PMID: 12880966
   PubMed Web of Science ®Google Scholar
• Carr-Wilkinson J, Griffiths R, Elston R, Gamble LD, Goranov B, Redfern CP, et al. Outcome of the p53-mediated DNA damage response in neuroblastoma is determined by morphological subtype and MYCN expression. Cell Cycle 2011; 10:3778 - 87; http://dx.doi.org/10.4161/cc.10.21.17973; PMID: 22052359
   PubMed Web of Science ®Google Scholar
• Eckerle I, Muth D, Batzler J, Henrich KO, Lutz W, Fischer M, et al. Regulation of BIRC5 and its isoform BIRC5-2B in neuroblastoma. Cancer Lett 2009; 285:99 - 107; http://dx.doi.org/10.1016/j.canlet.2009.05.007; PMID: 19497660
   PubMed Web of Science ®Google Scholar
• Westermann F, Muth D, Benner A, Bauer T, Henrich KO, Oberthuer A, et al. Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas. Genome Biol 2008; 9:R150; http://dx.doi.org/10.1186/gb-2008-9-10-r150; PMID: 18851746
   PubMed Web of Science ®Google Scholar
• Slack A, Chen Z, Tonelli R, Pule M, Hunt L, Pession A, et al. The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma. Proc Natl Acad Sci USA 2005; 102:731 - 6; http://dx.doi.org/10.1073/pnas.0405495102; PMID: 15644444
   PubMed Web of Science ®Google Scholar
• He J, Gu L, Zhang H, Zhou M. Crosstalk between MYCN and MDM2-p53 signal pathways regulates tumor cell growth and apoptosis in neuroblastoma. Cell Cycle 2011; 10:2994 - 3002; http://dx.doi.org/10.4161/cc.10.17.17118; PMID: 21862876
   PubMed Web of Science ®Google Scholar
• McKenzie PP, Guichard SM, Middlemas DS, Ashmun RA, Danks MK, Harris LC. Wild-type p53 can induce p21 and apoptosis in neuroblastoma cells but the DNA damage-induced G1 checkpoint function is attenuated. Clin Cancer Res 1999; 5:4199 - 207; PMID: 10632361
   PubMed Web of Science ®Google Scholar
• McKenzie PP, Danks MK, Kriwacki RW, Harris LC. P21Waf1/Cip1 dysfunction in neuroblastoma: a novel mechanism of attenuating G0-G1 cell cycle arrest. Cancer Res 2003; 63:3840 - 4; PMID: 12839982
   PubMed Web of Science ®Google Scholar
• Tweddle DA, Malcolm AJ, Cole M, Pearson AD, Lunec J. p53 cellular localization and function in neuroblastoma: evidence for defective G(1) arrest despite WAF1 induction in MYCN-amplified cells. Am J Pathol 2001; 158:2067 - 77; http://dx.doi.org/10.1016/S0002-9440(10)64678-0; PMID: 11395384
   PubMed Web of Science ®Google Scholar
• Keshelava N, Seeger RC, Groshen S, Reynolds CP. Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy. Cancer Res 1998; 58:5396 - 405; PMID: 9850071
   PubMed Web of Science ®Google Scholar
• Gewirtz DA. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 1999; 57:727 - 41; http://dx.doi.org/10.1016/S0006-2952(98)00307-4; PMID: 10075079
   PubMed Web of Science ®Google Scholar
• Rouaud P, Fiancette R, Vincent-Fabert C, Magnone V, Cogné M, Dubus P, et al. Mantle cell lymphoma-like lymphomas in c-myc-3’RR/p53+/- mice and c-myc-3’RR/Cdk4R24C mice: differential oncogenic mechanisms but similar cellular origin. Oncotarget 2012; 3:586 - 93; PMID: 22592113
   PubMed Web of Science ®Google Scholar
• Muth D, Ghazaryan S, Eckerle I, Beckett E, Pöhler C, Batzler J, et al. Transcriptional repression of SKP2 is impaired in MYCN-amplified neuroblastoma. Cancer Res 2010; 70:3791 - 802; http://dx.doi.org/10.1158/0008-5472.CAN-09-1245; PMID: 20424123
   PubMed Web of Science ®Google Scholar
• Lutz W, Stöhr M, Schürmann J, Wenzel A, Löhr A, Schwab M. Conditional expression of N-myc in human neuroblastoma cells increases expression of alpha-prothymosin and ornithine decarboxylase and accelerates progression into S-phase early after mitogenic stimulation of quiescent cells. Oncogene 1996; 13:803 - 12; PMID: 8761302
   PubMed Web of Science ®Google Scholar
• Agami R, Bernards R. Distinct initiation and maintenance mechanisms cooperate to induce G1 cell cycle arrest in response to DNA damage. Cell 2000; 102:55 - 66; http://dx.doi.org/10.1016/S0092-8674(00)00010-6; PMID: 10929713
   PubMed Web of Science ®Google Scholar
• Burgess A, Wigan M, Giles N, Depinto W, Gillespie P, Stevens F, et al. Inhibition of S/G2 phase CDK4 reduces mitotic fidelity. J Biol Chem 2006; 281:9987 - 95; http://dx.doi.org/10.1074/jbc.M512714200; PMID: 16476733
   PubMed Web of Science ®Google Scholar
• Wohlbold L, Merrick KA, De S, Amat R, Kim JH, Larochelle S, et al. Chemical genetics reveals a specific requirement for Cdk2 activity in the DNA damage response and identifies Nbs1 as a Cdk2 substrate in human cells. PLoS Genet 2012; 8:e1002935; http://dx.doi.org/10.1371/journal.pgen.1002935; PMID: 22927831
   PubMedGoogle Scholar
• Molenaar JJ, Ebus ME, Geerts D, Koster J, Lamers F, Valentijn LJ, et al. Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells. Proc Natl Acad Sci USA 2009; 106:12968 - 73; http://dx.doi.org/10.1073/pnas.0901418106; PMID: 19525400
   PubMed Web of Science ®Google Scholar
• Kitagawa M, Higashi H, Jung HK, Suzuki-Takahashi I, Ikeda M, Tamai K, et al. The consensus motif for phosphorylation by cyclin D1-Cdk4 is different from that for phosphorylation by cyclin A/E-Cdk2. EMBO J 1996; 15:7060 - 9; PMID: 9003781
   PubMed Web of Science ®Google Scholar
• Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993; 366:704 - 7; http://dx.doi.org/10.1038/366704a0; PMID: 8259215
   PubMed Web of Science ®Google Scholar
• Chan FK, Zhang J, Cheng L, Shapiro DN, Winoto A. Identification of human and mouse p19, a novel CDK4 and CDK6 inhibitor with homology to p16ink4. Mol Cell Biol 1995; 15:2682 - 8; PMID: 7739548
   PubMed Web of Science ®Google Scholar
• Guan KL, Jenkins CW, Li Y, O’Keefe CL, Noh S, Wu X, et al. Isolation and characterization of p19INK4d, a p16-related inhibitor specific to CDK6 and CDK4. Mol Biol Cell 1996; 7:57 - 70; PMID: 8741839
   PubMed Web of Science ®Google Scholar
• Gogolin S, Dreidax D, Becker G, Ehemann V, Schwab M, Westermann F. MYCN/MYC-mediated drug resistance mechanisms in neuroblastoma. Int J Clin Pharmacol Ther 2010; 48:489 - 91; PMID: 20557856
   PubMed Web of Science ®Google Scholar
• Johnson SM, Torrice CD, Bell JF, Monahan KB, Jiang Q, Wang Y, et al. Mitigation of hematologic radiation toxicity in mice through pharmacological quiescence induced by CDK4/6 inhibition. J Clin Invest 2010; 120:2528 - 36; http://dx.doi.org/10.1172/JCI41402; PMID: 20577054
   PubMed Web of Science ®Google Scholar
• Baughn LB, Di Liberto M, Wu K, Toogood PL, Louie T, Gottschalk R, et al. A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6. Cancer Res 2006; 66:7661 - 7; http://dx.doi.org/10.1158/0008-5472.CAN-06-1098; PMID: 16885367
   PubMed Web of Science ®Google Scholar
• Finn RS, Dering J, Conklin D, Kalous O, Cohen DJ, Desai AJ, et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res 2009; 11:R77; http://dx.doi.org/10.1186/bcr2419; PMID: 19874578
   PubMed Web of Science ®Google Scholar
• Konecny GE, Winterhoff B, Kolarova T, Qi J, Manivong K, Dering J, et al. Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer. Clin Cancer Res 2011; 17:1591 - 602; http://dx.doi.org/10.1158/1078-0432.CCR-10-2307; PMID: 21278246
   PubMed Web of Science ®Google Scholar
• Marzec M, Kasprzycka M, Lai R, Gladden AB, Wlodarski P, Tomczak E, et al. Mantle cell lymphoma cells express predominantly cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase activity. Blood 2006; 108:1744 - 50; http://dx.doi.org/10.1182/blood-2006-04-016634; PMID: 16690963
   PubMed Web of Science ®Google Scholar
• Wang L, Wang J, Blaser BW, Duchemin AM, Kusewitt DF, Liu T, et al. Pharmacologic inhibition of CDK4/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia. Blood 2007; 110:2075 - 83; http://dx.doi.org/10.1182/blood-2007-02-071266; PMID: 17537993
   PubMed Web of Science ®Google Scholar
• Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, Trachet E, et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther 2004; 3:1427 - 38; PMID: 15542782
   PubMed Web of Science ®Google Scholar
• Michaud K, Solomon DA, Oermann E, Kim JS, Zhong WZ, Prados MD, et al. Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts. Cancer Res 2010; 70:3228 - 38; http://dx.doi.org/10.1158/0008-5472.CAN-09-4559; PMID: 20354191
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Lorusso PM, Demichele A, Abramson VG, Courtney R, Randolph SS, et al. Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer. Clin Cancer Res 2012; 18:568 - 76; http://dx.doi.org/10.1158/1078-0432.CCR-11-0509; PMID: 22090362
   PubMed Web of Science ®Google Scholar
• Leonard JP, LaCasce AS, Smith MR, Noy A, Chirieac LR, Rodig SJ, et al. Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. Blood 2012; 119:4597 - 607; http://dx.doi.org/10.1182/blood-2011-10-388298; PMID: 22383795
   PubMed Web of Science ®Google Scholar
• Schwartz GK, LoRusso PM, Dickson MA, Randolph SS, Shaik MN, Wilner KD, et al. Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1). Br J Cancer 2011; 104:1862 - 8; http://dx.doi.org/10.1038/bjc.2011.177; PMID: 21610706
   PubMed Web of Science ®Google Scholar
• www.clinicaltrials.gov/ct2/results?/term=PD-0332991.
   Google Scholar
• Roberts PJ, Bisi JE, Strum JC, Combest AJ, Darr DB, Usary JE, et al. Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy. J Natl Cancer Inst 2012; 104:476 - 87; http://dx.doi.org/10.1093/jnci/djs002; PMID: 22302033
   PubMed Web of Science ®Google Scholar
• Sottile F, Gnemmi I, Cantilena S, D’Acunto WC, Sala A. A chemical screen identifies the chemotherapeutic drug topotecan as a specific inhibitor of the B-MYB/MYCN axis in neuroblastoma. Oncotarget 2012; 3:535 - 45; PMID: 22619121
   PubMed Web of Science ®Google Scholar
• Horvilleur E, Bauer M, Goldschneider D, Mergui X, de la Motte A, Bénard J, et al. p73alpha isoforms drive opposite transcriptional and post-transcriptional regulation of MYCN expression in neuroblastoma cells. Nucleic Acids Res 2008; 36:4222 - 32; http://dx.doi.org/10.1093/nar/gkn394; PMID: 18583365
   PubMed Web of Science ®Google Scholar
• Dunn T, Praissman L, Hagag N, Viola MV. ERG gene is translocated in an Ewing’s sarcoma cell line. Cancer Genet Cytogenet 1994; 76:19 - 22; http://dx.doi.org/10.1016/0165-4608(94)90063-9; PMID: 8076344
   PubMed Web of Science ®Google Scholar
• Henrich KO, Bauer T, Schulte J, Ehemann V, Deubzer H, Gogolin S, et al. CAMTA1, a 1p36 tumor suppressor candidate, inhibits growth and activates differentiation programs in neuroblastoma cells. Cancer Res 2011; 71:3142 - 51; http://dx.doi.org/10.1158/0008-5472.CAN-10-3014; PMID: 21385898
   PubMed Web of Science ®Google Scholar
• Afanasyeva EA, Mestdagh P, Kumps C, Vandesompele J, Ehemann V, Theissen J, et al. MicroRNA miR-885-5p targets CDK2 and MCM5, activates p53 and inhibits proliferation and survival. Cell Death Differ 2011; 18:974 - 84; http://dx.doi.org/10.1038/cdd.2010.164; PMID: 21233845
   PubMed Web of Science ®Google Scholar
• Ehemann V, Hashemi B, Lange A, Otto HF. Flow cytometric DNA analysis and chromosomal aberrations in malignant glioblastomas. Cancer Lett 1999; 138:101 - 6; http://dx.doi.org/10.1016/S0304-3835(98)00383-8; PMID: 10378780
   PubMed Web of Science ®Google Scholar
• Brueckner LM, Sagulenko E, Hess EM, Zheglo D, Blumrich A, Schwab M, et al. Genomic rearrangements at the FRA2H common fragile site frequently involve non-homologous recombination events across LTR and L1(LINE) repeats. Hum Genet 2012; 131:1345 - 59; http://dx.doi.org/10.1007/s00439-012-1165-3; PMID: 22476624
   PubMed Web of Science ®Google Scholar